XTL Biopharmaceuticals ($XTLB) has struck an interesting deal to land a badly-needed late-stage therapy for its pipeline. The company gained an exclusive license for all the technology on hand at Israel's MinoGuard. The developer has completed a...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.